Morocco’s Cooper Pharma to build antibiotic manufacturing plant in Rwanda


Cooper Pharma, a Moroccan pharmaceutical maker, has inked a deal to build an antibiotic manufacturing facility in Rwanda.

The facility would be the first of its kind in the country, a state official told allAfrica. It is the second such plant construction deal by Cooper, which previously said it signed a deal in Abidjan, Ivory Coast.

The plant in Rwanda is slotted to be built on a nearly 33,000 square-foot plot of land in the Kigalir Special Economic Zone. The facility is expected to open in 2019 and will produce beta-lactam antibiotics, which are among the most commonly prescribed drugs, including Penicillins.


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

The deal, which was designed to help meet local pharmaceutical needs, was announced during a three-day state visit by a Moroccan delegation led by King Mohamed VI.

"The market entry of Cooper Pharma… is in line with the long held wish by the government to have a pharmaceutical plant in Rwanda,” Serge Kamuhinda, the COO of the Rwanda Development Board, told allAfrica. “This will reduce our trade deficit and boost exports.”


Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.